cerca CERCA
Venerdì 26 Febbraio 2021
Aggiornato: 02:53
Temi caldi


SunRock Biopharma and GenScript ProBio Enter into a Collaboration Agreement to Develop Novel Monoclonal Antibody Program

NANJING, China, Feb. 22, 2021 /PRNewswire/ -- On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock's CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug prod...

Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab

BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®), demonstrated encouraging anti-tumor activity in an ongoing Phase I/II clinical trial in Australia. The trial is a multicenter, open label study, with an initial multiple-dose-escalation phase designed t...

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study started at the University Clinic of Navarra, Spain, under the supervision of Pr. Ignacio Melero, Immunologist and Senior Investigator at Centro de Investigación Méd...

WuXi Biologics adopt Purolite Life Sciences Protein A resin for monoclonal antibody therapies

CARDIFF, South Wales, Nov. 5, 2020 /PRNewswire/ -- Purolite Ltd., a global manufacturer of resin-based separation, purification and extraction technologies, today announces that it will supply its Protein A capture resin, Praesto® Jetted A50 to WuXi Biologics for immediate use. WuXi Biologics, a global company with leading open-access biologics technology, will utilize Praesto® Jetted A50 to provide their customers with additional choices for affinity chromatography resins for a range of downstre...

ora in
Prima pagina
in Evidenza